quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·8d
PRRelease
Metagenomi Therapeutics Inc. logo

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

MGX· Metagenomi Therapeutics Inc.
Health Care
Original source

Companies

  • MGX
    Metagenomi Therapeutics Inc.
    Health Care

Recent analyst ratings

  • May 7UpdateH.C. Wainwright$10.00
  • May 2UpdateJP Morgan$6.00
  • Mar 5UpdateTD Cowen-
  • Mar 5UpdateBMO Capital Markets$22.00
  • Mar 5UpdateJP Morgan$16.00
  • Mar 5UpdateJefferies$23.00

Related

  • INSIDER20d
    SEC Form 4 filed by Irish Jian
  • INSIDER20d
    SEC Form 4 filed by Wein Matthew
  • INSIDER20d
    SEC Form 4 filed by Wapnick Pamela
  • INSIDER45d
    Chief Financial Officer Wapnick Pamela sold $2,530 worth of shares (1,581 units at $1.60), decreasing direct ownership by 0.84% to 187,375 units (SEC Form 4)
  • INSIDER45d
    Officer Wein Matthew sold $771 worth of shares (482 units at $1.60), decreasing direct ownership by 0.42% to 114,549 units (SEC Form 4)
  • INSIDER45d
    Chief Executive Officer Irish Jian gifted 228,462 shares and sold $2,571 worth of shares (1,607 units at $1.60), decreasing direct ownership by 41% to 333,770 units (SEC Form 4)
  • SEC49d
    SEC Form S-8 filed by Metagenomi Therapeutics Inc.
  • SEC49d
    SEC Form 10-K filed by Metagenomi Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022